A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Beste, Christian ^a   Stock, Ann Kathrin ^a   Ness, Vanessa ^a   Hoffmann, Rainer ^b   Lukas, Carsten ^c   Saft, Carsten ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b St Josef Hospital   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; DISEASE COURSE; FEMALE; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MALE; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; YOUNG ADULT;

EID: 84877735576     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01797     Document Type: Article

References (38)

1. Ross, C. A. & Tabrizi, S. J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-88 (2011).
2. Weir, D. W., Sturrock, A. & Leavitt, B. R., Development of biomarkers for Huntington's disease. Lancet Neurol. 10, 573-590 (2011).
3. Tabrizi, S. J. et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 8, 791-801 (2009).
4. Paulsen, J. S. et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 79, 874-880 (2008).
5. Orth, M. et al. Observing Huntington's disease: the European Huntington's disease Networks REGISTRY. J. Neurol. Neurosurg. Psychiatry 82, 1409-1412 (2011).
6. Tabrizi, S. J. et al. Potential endpoints for clinical trails in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 11, 42-53 (2012).
7. O'Keefe, G. C., Michell, A. W. & Marker, R. A. Biomarkers in Huntington's and Parkinson's disease. Ann. N. Y. Acad. Sci. 1180, 97-110 (2009).
8. Beste, C. et al. Levels of error processing in Huntington' disease: a combined study using event-related potentials and voxel-based morphometry. Hum. Brain Mapp. 29, 121-130 (2008). (Pubitemid 351294942)
9. Beste, C. et al. Functional compensation or pathology in cortico-subcortical interactions in preclinical Huntington's disease. Neuropsychologia 45, 2922-2930 (2007). (Pubitemid 47374741)
10. Nguyen, L., Bradshaw, J. L., Stout, J. C., Croft, R. J. & Georgiou-Karistianis, N. Electrophysiological measures as potential biomarkers in Huntington's disease: review and future directions. Brain. Res. Rev. 64, 177-194 (2010).
11. Henley, S. M., Bates, G. P. & Tabrizi, S. J. Biomarkers for neurodegenerative diseases. Curr. Opin. Neurol. 18, 698-705 (2005). (Pubitemid 41669144)
12. Aron, A. R. et al. Taskset switching deficits in early-stage Huntington's disease: implications for basal ganglia function. J. Cogn. Neurosci. 15, 629-642 (2003). (Pubitemid 36871877)
13. Kehagia, A. A., Cools, R., Barker, R. & Robbins, T. W. Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease. Neuropsychologia 47, 1117-1127 (2009).
14. Redgrave, P. et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat. Rev. Neurosci. 11, 760-772 (2010).
15. Plenz, D. When inhibition goes incognito: feedback interaction between spiny projection neurons in striatal function. Trends Neurosci. 26, 436-443 (2003). (Pubitemid 37288979)
16. Thomas, E. A. et al. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum. Mol. Genet. 20, 1049-1060 (2011).
17. Cepeda, C., Wu, N., Andre, V. M., Cummings, D. M. & Levine, M. S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 81, 253-271 (2007). (Pubitemid 46528639)
18. Botvinick, M. M., Cohen, J. D. & Carter, C. S. Conflict monitoring and anterior cingulate cortex: an update. Trends Cogn. Sci. 8, 539-546 (2004). (Pubitemid 39536251)
19. Beste, C. et al.Mechanismsmediating parallel action monitoring in fronto-striatal circuits. Neuroimage 62, 137-146 (2012).
20. Langbehn, D. R., Brinkman, R. R., Falush, D., Paulsen, J. S. & Hayden, M. R. International Huntington's disease collaborative group. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 65, 267-277.
21. Stout, J. C. et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 83, 687-694 (2012).
22. Campodonico, J. R., Codori, A. M. & Brandt, J. Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. J. Neurol. Neurosurg. Psychiatry 61, 621-624 (1996). (Pubitemid 27023342)
23. Witjes-Ane, M. N. et al. Longitudinal evaluation of presymptomatic carriers of Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 19, 310-317 (2007).
24. Gajewski, P. D., Kleinsorge, T.&Falkenstein, M. Electrophysiological correlates of residual switch costs. Cortex 46, 1138-1148 (2010).
25. Folstein, J. R. &Van Petten, C. Influence of cognitive control and mismatch on the N2 component of the ERP: a review. Psychophysiology 45, 152-170 (2008). (Pubitemid 350233271)
26. Mayr, U. Age differences in the selection of mental sets: the role of inhibition, stimulus ambiguity, and response-set overlap. Psychol. Aging 16, 96-109 (2000). (Pubitemid 32230558)
27. Karayanidis, F., Coltheart, M., Michie, P. T. & Murphy, K. Electrophysiological correlates of anticipatory and poststimulus components of task switching. Psychophysiology 40, 329-348 (2003). (Pubitemid 36596903)
28. Polich, J. Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol 118, 2128-2148 (2007). (Pubitemid 47385341)
29. Willemssen, R., Falkenstein, M., Schwarz, M., Müller, T. & Beste, C. Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control. Neurobiol. Aging 32, 327-335 (2011).
30. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov. Disord. 11, 136-142 (1996).
31. Perrin, F., Pernier, J., Bertrand, O. & Echallier, J. F. Spherical splines for scalp potential and current density mapping. Electroencephalogr. Clin. Neurophysiol. 72, 184-187 (1989). (Pubitemid 19045239)
32. Nunez, P. L. & Pilgreen, K. L. The spline-laplacian in clinical neurophysiology: a method to improve EEG spatial resolution. J. Clin. Neurophysiol. 8, 397-413.
33. Roach, B. J. & Mathalon, D. H. Event-related EEG time-frequency analysis: an overview of measures and an analysis of early gamma band phase locking in schizophrenia. Schizophr. Bull. 34, 907-926 (2008).
34. Ocklenburg, S., Güntürkün, O. & Beste, C. Lateralized neural mechanisms underlying the modulation of response inhibition processes. Neuroimage 55, 1771-1778 (2011).
35. Beste, C. et al. Functional 5-HT1a receptor polymorphism selectively modulates error-specific subprocesses of performance monitoring. Hum. Brain Mapp. 31, 621-630 (2010).
36. Aylward, E. H. et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 63, 66-72 (2004). (Pubitemid 38943780)
37. Saft, C., Andrich, J., Meisel, N. M., Przuntek, H. & Müller, T. Congruent deterioration of complex and simple movements in patients with Huntington's disease. J. Neural. Transm. Suppl. 68, 97-104 (2004). (Pubitemid 39215442)
38. Andrich, J., Saft, C., Ostholt, N. & Müller, T. Assessment of simple movements and progression of Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 78, 405-407 (2007). (Pubitemid 46580553)